Keyword: Realm Therapeutics

The deal effectively sees Essa trade its shares for Realm’s cash, giving it the financial means to advance its pipeline of cancer drugs.

The actions are part of the biotech’s ongoing efforts to seek a way out of its R&D-triggered troubles.